0.57
-0.0556(-8.87%)
Currency In USD
| Previous Close | 0.63 |
| Open | 0.63 |
| Day High | 0.63 |
| Day Low | 0.56 |
| 52-Week High | 4.32 |
| 52-Week Low | 0.56 |
| Volume | 766,262 |
| Average Volume | 2.31M |
| Market Cap | 5.21M |
| PE | -0.16 |
| EPS | -3.64 |
| Moving Average 50 Days | 0.81 |
| Moving Average 200 Days | 1.07 |
| Change | -0.06 |
If you invested $1000 in Palisade Bio, Inc. (PALI) 10 years ago, it would be worth $0 as of September 09, 2025 at a share price of $0.571. Whereas If you bought $1000 worth of Palisade Bio, Inc. (PALI) shares 5 years ago, it would be worth $0.21 as of September 09, 2025 at a share price of $0.571.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)
GlobeNewswire Inc.
Sep 05, 2025 12:45 PM GMT
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Patient dosing expected to commence in H2 2025; Topline data anticipated in Q1 2026 Continued progress toward Phase 2 IND
Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108
GlobeNewswire Inc.
Aug 25, 2025 1:00 PM GMT
– Moderated discussion with leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan – Segment provides further insight into the need for more effective treatment options for FSCD and how PALI-21
Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108
GlobeNewswire Inc.
Aug 07, 2025 1:15 PM GMT
PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) Colon tissu